secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProMIS Neurosciences Inc. (PMN)
CIK:        0001374339
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001558370-23-019067
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProMIS Q3 net loss $2.4M, cash $16.9M; starts Phase 1a PMN310 Alzheimer's trial
-------------------------------------------------------------------------------

- Net loss $2.4M in Q3 2023 vs $6.0M in Q3 2022; R&D expenses dropped to $1.1M from $4.6M.
- Cash $16.9M at Sep 30, 2023, up from $5.9M at Dec 31, 2022, after $20.4M gross PIPE proceeds.
- Phase 1a trial of PMN310 for Alzheimer's: first subjects dosing expected Nov 2023; early cohort results in H1 2024.
- Raised $20.4M via private placement of ~10M shares and ~955K pre-funded warrants in August 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374339/000155837023019067/0001558370-23-019067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374339/000155837023019067/pmn-20231114x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-019067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer